BRPI0510691A - marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento - Google Patents

marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento

Info

Publication number
BRPI0510691A
BRPI0510691A BRPI0510691-5A BRPI0510691A BRPI0510691A BR PI0510691 A BRPI0510691 A BR PI0510691A BR PI0510691 A BRPI0510691 A BR PI0510691A BR PI0510691 A BRPI0510691 A BR PI0510691A
Authority
BR
Brazil
Prior art keywords
methods
treatment
present
haplotype
determine response
Prior art date
Application number
BRPI0510691-5A
Other languages
English (en)
Inventor
Beena Koshy
Bradley J Dain
Madan Kamur Anant
Ping Zhan
Original Assignee
Genaissance Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaissance Pharmaceuticals filed Critical Genaissance Pharmaceuticals
Publication of BRPI0510691A publication Critical patent/BRPI0510691A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MARCADORES DE HAPLóTIPOS E MéTODOS DE USO DOS MESMOS PARA DETERMINAR RESPOSTA AO TRATAMENTO. A presente invenção relaciona-se a métodos para diagnóstico ou previsão da capacidade de resposta ao tratamento, como Alefacept, por determinação da presença de um nucleotídeo em um ou mais sítios polimórficos em um marcador de haplótipo. A presente invenção identifica múltiplos haplótipos que estão associados à resposta a Alefacept. Os marcadores de haplótipo identificados pela presente invenção e métodos da invenção podem ser particularmente úteis para o diagnóstico ou previsão da suscetibilidade a doenças da pele, como Psoríase.
BRPI0510691-5A 2004-05-04 2005-05-04 marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento BRPI0510691A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56837104P 2004-05-04 2004-05-04
PCT/US2005/015531 WO2005112568A2 (en) 2004-05-04 2005-05-04 Haplotype markers and methods of using the same to determine response to treatment

Publications (1)

Publication Number Publication Date
BRPI0510691A true BRPI0510691A (pt) 2007-12-26

Family

ID=35428732

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510691-5A BRPI0510691A (pt) 2004-05-04 2005-05-04 marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento

Country Status (9)

Country Link
US (1) US20080020383A1 (pt)
EP (1) EP1747291A2 (pt)
KR (1) KR20070011558A (pt)
CN (1) CN1997756A (pt)
BR (1) BRPI0510691A (pt)
CA (1) CA2565804A1 (pt)
IL (1) IL178970A0 (pt)
MX (1) MXPA06012744A (pt)
WO (1) WO2005112568A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149612A1 (en) * 2008-07-29 2010-02-03 Merck Serono SA Genetic markers of response to efalizumab
GB2467162A (en) 2009-01-26 2010-07-28 Sharp Kk Fabrication of nitride nanoparticles
GB2467161A (en) 2009-01-26 2010-07-28 Sharp Kk Nitride nanoparticles
SMT201700583T1 (it) * 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
WO2015130891A2 (en) * 2014-02-26 2015-09-03 Illumicure Inc. Ultraviolet phototherapy apparatuses and methods
US20190168016A1 (en) 2016-02-09 2019-06-06 Luma Therapeutics, Inc. Methods, compositions and apparatuses for treating psoriasis by phototherapy
CN114085873A (zh) * 2021-11-16 2022-02-25 珠海中科先进技术研究院有限公司 一种癌细胞状态辨识基因电路组及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579844A (en) * 1976-05-13 1986-04-01 Johnson & Johnson Topical anti-inflammatory drug therapy
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
JPH0763830B2 (ja) * 1985-11-26 1995-07-12 アスモ株式会社 ダイカスト鋳造金型への離型剤塗布方法
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
AU660981B2 (en) * 1991-03-12 1995-07-13 Astellas Us Llc CD2-binding domain of lymphocyte function associated antigen 3
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
WO1996022303A1 (en) * 1995-01-16 1996-07-25 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound - fatty acid conjugates
WO2000012113A2 (en) * 1998-08-31 2000-03-09 Biogen, Inc. Method of modulating memory effector t-cells using a cd2-binding agent, and compositions
US6337337B1 (en) * 1998-09-03 2002-01-08 Carol J. Buck Methods for treating disorders responsive to DHFR-inhibition
MXPA03006919A (es) * 2001-02-01 2004-06-02 Biogen Inc Metodos para tratar o prevenir trastornos de la piel usando agentes de union a cd2.
WO2002069904A2 (en) * 2001-03-02 2002-09-12 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease

Also Published As

Publication number Publication date
MXPA06012744A (es) 2007-02-19
WO2005112568A3 (en) 2006-05-11
US20080020383A1 (en) 2008-01-24
WO2005112568A2 (en) 2005-12-01
KR20070011558A (ko) 2007-01-24
EP1747291A2 (en) 2007-01-31
IL178970A0 (en) 2007-03-08
CA2565804A1 (en) 2005-12-01
CN1997756A (zh) 2007-07-11

Similar Documents

Publication Publication Date Title
Ikeda et al. HLA class I markers in Japanese patients with carbamazepine‐induced cutaneous adverse reactions
EP4293358A3 (en) Volatile organic compounds as cancer biomarkers
Chen et al. Mutation of an A-kinase-anchoring protein causes long-QT syndrome
James et al. Complex epigenetic regulation of engrailed-2 (EN-2) homeobox gene in the autism cerebellum
MX2009005651A (es) Marcadores geneticos para el manejo de riesgo de la arritmia cardiaca.
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
BRPI0507442A (pt) métodos de diagnóstico e tratamento de pré-eclampsia ou eclampsia
WO2008069975A3 (en) Methods of using f-spondin as a biomarker for cartilage degenerative conditions
BRPI0710436A8 (pt) método para determinar se um paciente é portador de hla-b*1502, kit para determinar se um paciente é portador de hla-b*1502,kit de três sondas para determinar se um paciente é portador de hla-b*1502, método para determinar se um paciente é portador de hla-b*5801, kit para determinar se um paciente é portador de hla-b*5801, kit de três sondas para determinar se um paciente é portador de hla-b*5801 e método para determinar se um composto é um candidato que induz uma reação adversa causada por droga (adr) em um paciente que é portador de um alelo de hla associado com a adr induzida por um droga
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
BRPI1013546A2 (pt) usos de um inibidor da timidilato sintase e de uma terapia anticâncer
BRPI0712225A8 (pt) métodos para prever e monitorar a eficácia da terapia antagonista de igf-1r
WO2012018535A3 (en) Wellness panel
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
EP2637020A3 (en) Predictive markers for ovarian cancer
JP2016536012A5 (pt)
BR112013006528A2 (pt) fosfolipidoma de câncer
BR112013013457A2 (pt) métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composições
BR112022007996A2 (pt) Métodos para o tratamento e uso de biomarcadores para predizer a sensibilidade clínica à 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
BR112015008042A2 (pt) diagnósticos complementares para terapia com inibidor de quinase da família tec
Takemoto et al. Hair mi R‐29a levels are decreased in patients with scleroderma
WO2010054195A3 (en) Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
BRPI0510691A (pt) marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento
Khan et al. PCR/RFLP-based analysis of genetically distinct Plasmodium vivax population of Pvmsp-3α and Pvmsp-3β genes in Pakistan
BRPI0412110A (pt) genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.